

UPDATE:

June 30, 2020

B. Braun Statement on Cybersecurity Vulnerability with Ripple20 Communications Software

B. Braun Medical is aware of the Cybersecurity and Infrastructure Security Agency (CISA) notification concerning the Cybersecurity Vulnerability ICS-VU-035787 Ripple20 reported by Treck Inc., a third party software vendor. The vulnerabilities exist in the third party software used for network communication. The Treck software is used in the B. Braun Outlook[®] ES Safety Infusion Pump System.

According to the CISA report, the vulnerability could affect a variety of devices in the marketplace and expose them to cybersecurity threats. The vulnerability is present because some medical devices utilize the Treck TCP/IP software stack in the medical device to communicate data with communication networks.

B. Braun's analysis determined that the Outlook 400ES infusion pump is the only product in our portfolio that uses the vulnerable source code in its wireless network communications software system.

The vulnerable software is not used in the Space Infusion pump family (Infusomat, Perfusor, Space Station, and Space Wireless Battery), DoseTrac Server, DoseLink Server, Space Online Suite Server, Apex Compounder and Pinnacle Compounder.

To date, B. Braun has received 24 patches from Treck to resolve vulnerabilities in the software. We have analyzed the patches and determined that 20 of them are not applicable to the Outlook 400 ES platform because those 20 patches apply to features that are not part of the design and not built into the infusion pump. The four remaining patches continue to be analyzed to determine the scope, severity, and impact of each vulnerability. The four vulnerabilities are:

CVE-2020-11903 - scored by Treck Inc with a CVSS value 5.3 (Medium Severity)
CVE-2020-11906 - scored by Treck Inc with a CVSS value 5.0 (Medium Severity)
CVE-2020-11912 - scored by Treck Inc with a CVSS value 3.7 (Low Severity)
CVE-2020-11914 - scored by Treck Inc with a CVSS value 3.1 (Low Severity)

B. Braun continues to work with CISA, DHS and Treck to complete the vulnerability analysis of the software used in the Outlook 400ES infusion pump.

B. Braun ensures high security standards throughout the product life cycle by using globally accepted standard test and verification methods. We have established processes to monitor the latest vulnerabilities, threats, or risks and will proactively implement measures as required. No actions by our customers are recommended at this time.

Further information can be found at the Cybersecurity and Infrastructure Security Agency of the Department of Homeland Security. (<https://www.us-cert.gov/ics>)